The Trump government has moved to terminate financing for a wide range of HIV vaccine research, and says that the current approaches are sufficient to prevent the virus, say various scientists and federal health officers.
This story originally continued CBS News.
It cannot be re -published.
Reports that the financing would not be expanded were passed on to researchers who were told on 30 May National Institutes of Health civil servants who Department of Health and Human Services Instead, to “deal with currently available approaches to eliminate HIV”.
The cutbacks will close two large HIV vaccine research efforts that are first financed by the NIH in 2012 At the Duke Human Vaccine Institute and the Scripts Research Institute, scientists said. A Moderna spokesperson said the vaccine manufacturer clinical examinations A break has also been placed via the NIH’s HIV vaccinations.
A senior nih officer said that the HHS had instructed the agency not to spend any financing for HIV vaccine investigation in the next tax year, with only a handful of exceptions.
A budgetary change of rule that is specifically aimed at HIV vaccine research is also expected to lead to a new reduction of the AHIHs Awards for studies initiated by scientists, an officer said.
The change, which must be completed soon, blows the accounting for the prior costs of studies in HIV -vaccines that are financed by the agency. Instead of the costs of a five-year subsidy that will be distributed in five years, the NIH is planning to make HIV vaccine dollars of multi-year subsidies that all count for a year, the official said, making it more difficult for them to be financed.
A HHS spokesperson said CBS News that “complex and duplicative health programs have resulted in a serious duplication of efforts,” say that “27 separate programs that tackle HIV/AIDS” had published $ 7.5 billion.
“The administration is of the opinion that the United States should have the best medical research in the world. That is why we promote policy to maximize the impact of every federal taxpayer dollar and to guarantee good supervision of this financing,” said HHS spokesperson Emily Hilliard.
Hilliard claimed that “critical HIV/AIDS programs will continue” under the new agency that health and human service secretary Robert F. Kennedy Jr. proposed to create the administration for a healthy America.
“For the design and development of HIV vaccine we started seeing light at the end of the tunnel after many years of research. This is a terrible time to cut it off. We are starting to come close. We get good results from clinical tests,” we said Dennis BurtonAn immunology professor of Scripps Research.
Burton warned that the HIV vaccine investigation of his institution could not simply be displayed, even if a future administration decided to change course about HIV financing. He said that current experiments would be closed and that researchers who have gathered to study the problem would be forced to concentrate their career on other topics.
“This is a decision with the consequences that will linger. This is a setback of probably ten years for HIV -vaccine research,” said Burton.
The cancellation of the funds comes weeks before the FDAs June 19 Deadline To decide on approval of Lenacapavir, an annual injectable medicine to prevent HIV.
The medicine, which is brought to the commercial market by drug maker Gilead Sciences, builds up Nih supported investigation In earlier HIV medication. The availability of the drug can lead to a significant fall in HIV cases worldwide, since then Found a study It was 100% effective in preventing transmission.
A NIH officer, who was not authorized to speak publicly, punished the claim that the effectiveness of current HIV prevention strategies meant that a vaccine was no longer necessary. “The only way to end the HIV epidemic in the US and to help Pandemie worldwide” is with a vaccine, said the civil servant.
The development of an effective HIV vaccine has been an elusive target for researchers, although scientists have praised recent breakthroughs in the field.
“HIV has established road vaults for us who are fighting against the fighting, which are unparalleled in vaccinology. We have had to learn what each of the roadblocks is and to think of ways to overcome it. This virus is so fast,” said Duke Professor of Medicine Barton Ford Haynes, who is part of the Duke their their theirs their theirs their theirs their theirs their theirs their their theirs their theirs their theirs their theirs their their theirs their theirs their theirs their their theirs their their theirs their theirs their their theirs their theirs their theirs their their their theirs their theirs their their theirs their their theirs their their theirs their their theirs their their theirs their their theirs their their theirs their their theirs their their theirs’s their theirs their their theirs’s their theirs their their theirs’s their theirs their their theirs’s their theirs’s their theirs’s their their theirs’s their theirs.
Haynes said that the work of his institute essentially combined different vaccines as part of a strategy to design an effective HIV vaccine.
He praised Lenacapavir as a “beautiful development for the field”, but said there was still a need for a vaccine. Lenacapavir requires every six months to remain effective, a challenging proposition, even before steep cuts on the Centers for Disease Control and Prevention’s inner HIV programs and the US supported by the US/AIDS-Buitenland utensils.
“The hope was that adding an HIV vaccine to all the preventive measures that we have would finally enable us to end the pandemic,” Haynes said.
#Trump #administration #ends #HIV #vaccinations #scientists #officials #KFF #Health #News